Znaczenie rokownicze surowiczego stężenia białka C-reaktywnego (CRP) i fragmentów cytokeratyny 19 (Cyfra 21-1), ale nie antygenu rakowopłodowego (CEA) u chorych leczonych operacyjnie z powodu niedrobnokomórkowego raka płuca
Introduction
Surgical treatment in the early stage of non -small cell lung cancer (NSCLC) is associated with the best prognosis. Current 5-year survival rates are 50-70% in pathological stage I of the disease and 43-61% in stage II [1] . Despite extensive preoperative evaluation, still a significant proportion of the patients are diagnosed with pathological stage III disease after surgery. Such a finding is combined with substantially worse survival (5-year survival rates -10-30%), even with the use of adjuvant therapy [2] .
Stage of the disease is the strongest prognostic indicator; nevertheless, other prognostic factors such as age, tumour histology, lymphatic and blood vessels involvement are described in the literature [3, 4] .
The role of preoperative assessment of tumour markers and inflammatory proteins as prognostic indicators is still not established.
The aim of the present study was to assess the value of preoperative tumour markers [cytokeratin 19 fragments (Cyfra 21-1), carcinoembryonic antigen (CEA)] and C-reactive protein (CRP) in predicting long-term survival in surgically treated non-small cell lung cancer patients.
Material and methods
Fifty consecutive NSCLC patients referred in 2004 to the Department of Thoracic Surgery of the National Institute of Tuberculosis and Lung Diseases were prospectively enrolled into the study group. Written consent for participation in the study was obtained in all of them. The group included 38 males and 12 females, and median age was 65 years (range 42-89 years). Histological types of tumours, according to WHO classification from 2004 [5] , were as follows: adenocarcinoma -in 25 patients, squamous cell lung cancer -in 21, adenosquamous lung cancer -in 4 patients. Preoperative staging was based on chest and upper abdomen computed tomography (CT), fibre-optic bronchoscopy and abdomen ultrasonographic examination. Brain CT scan was performed in four patients due to clinical suspicion of CNS metastases -the results were negative in all of them. Mediastinoscopy was performed in six patients with the suspicion of N2 disease based on chest CT (mediastinal lymph nodes enlargement > 1 cm in the short axis). The results were negative in all of them. The clinical staging (including the negative result of mediastinoscopy), according to WHO sixth edition [6] , www.pneumonologia.viamedica.pl was: Ia in 12 patients, Ib in 26 patients, IIa in 3 patients and IIb in 9 patients.
Surgical treatment consisted of the following: lobectomy in 42 patients, bilobectomy in 1 pt and pneumonectomy in 7 patients.
Pathological stage of the disease was as follows: Ia in 13 patients, Ib in 20, IIb in 9 patients, IIIa in 4, IIIb in 3 and IV (metastases to the other lobe) in 1 pt. Pathological tumour size (pT) was: pT1 in 13 patients, pT2 in 32, pT3 in 2, and pT4 in 3 patients.
The degree of differentiation of lung cancer was determined in 47 tumours: 14 were poorly differentiated (G3), 29 were moderately differentiated (G2) and 4 were well differentiated (G1). Mean (± SD) and median (95%CI) percentage of necrotic cells were 21.74% ± 16.9% and 20% (0-80)%, respectively.
The patients in whom pathological stages IIIa-IV of NSCLC were recognised after surgical treatment received adjuvant therapy (chemo ± radiotherapy).
Carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (Cyfra 21-1) concentrations were measured in serum taken before surgery and before mediastinoscopy. Cobas Core immunoassay was used. The cut-off values provided by the assay's manufacturer were applied: 5 ng/mL for CEA and 3.3 ng/mL for Cyfra 21-1. Serum CRP was assessed in 46 patients by Hitachi analyser. The cut off value was 5 mg/L. The CEA, Cyfra 21-1 and CRP values with highest prognostic significance were identified with the use of ROC curves.
The survival time was calculated from the date of surgical treatment until death or until the end of observation time (five years).
Kruskal-Wallis one-way analysis of variance (on ranks) was used to compare marker values in different subgroups of patients. Death hazard ratio (HR) was assessed with single and multiple regression analysis. P < 0.05 was considered significant.
Results
Median survival in the presented group of patients was 72.5 (4-108) months. The percentages of 1-, 2-, 3-, 4-and 5-year survival were: 88%, 72%, 60%, 54% and 54%, respectively.
Median preoperative serum Cyfra 21-1 concentration was 2.1 (95%CI 0.7-14.5) ng/mL. In 16/50 patients (32%) Cyfra 21-1 values exceeded 3.3 ng/mL. A tendency towards higher Cyfra 21-1 values in the patients with higher pathological stages of the disease, comparing to the patients with lower stages of the disease, was found (Table 1) . Median Cyfra 21-1 in stages Ia-IIb was 2.03 (95%CI 1-6.76) ng/mL, and in stages III-IV it was 3.6 (95%CI 1-14.5) ng/mL (p = 0.1). The values of Cyfra 21-1 did not correlate with the histological type of tumour (Table 2 ) nor with the percentage of tumour necrosis. According to ROC analysis, the Cyfra 21-1 value with optimal prognostic significance was 2 ng/mL. Median survival times in the patients with Cyfra 21-1 < = 2 ng/mL (23 patients) and > 2 ng/mL (27 patients) were 79 (95%CI 14.85-88.2) months and 29 (95%CI 5.7-87.6) months, respectively (p < 0.026). The survival curves of the patients with Cyfra 21-1 ≤ 2 ng/mL and > 2 ng/mL are presented in Figure 1 .
Median preoperative serum CEA concentration was 2.68 (95%CI 0.87-72.7) ng/mL. CEA exceeding 5 ng/mL was found in 11/50 patients (22%). CEA serum concentration depended on the histological type of tumour (Table 2 ). Significantly higher median serum CEA was found in the patients with adenocarcinoma, comparing to the patients with squamous cell lung cancer -4.38 (Table 1) . ROC analysis failed to indicate an optimal prognostic CEA value. Median serum CRP was 5.45 (95%CI 0-122.6) mg/L. Values exceeding 5 mg/L were found in 26/46 patients (60%). Significant dependence was found between serum CRP and pathological tumour size (pT). Median CRP values in pT1, pT2 and pT3+4 tumours were: 2.8 mg/L, 6.9 mg/L and 23.5 mg/L, respectively (p < 0.05) ( Table 3) .
ROC analysis revealed that CRP > 10 mg/L was the optimal prognostic cut-off value. Median survival time of 28 patients with CRP ≤ 10 mg/L was 79 (14.85-88.2) months, and for 18 patients with CRP > 10 mg/L it was 29.5 (5.7-87.6) months (p = 0.046). Survival curves of the patients with serum CRP ≤ 10 mg/L and > 10 mg/L are presented in Figure 2 .
Univariate analysis revealed that out of the factors known before lung surgery, only serum CRP > 10 mg/L and Cyfra 21-1 exceeding 2 ng/mL were significant prognostic indicators. No prognostic significance for patient age, sex, histological type of tumour and clinical stage of disease was found (Table 4) . Among the parameters known after surgical treatment, pathological stage of the disease and pT value were significant prognostic indicators (Table 4) . No prognostic significance of the percentage of necrotic tumour cells and the degree of tumour differentiation was found.
Multivariate analysis taking into account only pretreatment prognostic parameters (Cyfra 21-1 > 2 ng/mL and CRP > 10 mg/L) revealed that none of the markers was an independent prognostic factor. Multivariate analysis taking into account all significant prognostic variables, both pretreatment and post-treatment, revealed that only pathological stage of disease was an independent prognostic indicator ( Table 4) .
Discussion
CRP is a marker of inflammation and tissue damage. Its prognostic significance is well esta-www.pneumonologia.viamedica.pl blished in cardiovascular diseases [7] . Shields et al. found that inflammation score assessed by CRP, b-cell attracting chemokine 1 (macrophage -derived chemokine) and interleukin 1 receptor antagonist provided good separation in 10-year lung cancer cumulative risk among current and former smokers and was of prognostic significance [8] .
A large epidemiological study of 33,567 participants with various neoplastic diseases conducted by Ko et al. [9] indicated that CRP ≥ 3 mg/L was associated with higher mortality in lung cancer.
In the present study, preoperative serum CRP concentration > 10 mg/L was of prognostic significance, and the risk of death was twice as high in the group of patients with CRP > 10 mg/L comparing to the others. A similar observation concerning CRP prognostic value was made by O'Dowd et al. [10] , who found significantly worse survival in patients with CRP exceeding 10 mg/L comparing to those with CRP equal to or lower than 10 mg/L (26.2 months and 75.9 months, respectively). Hara et al. [11] found the prognostic significance of CRP > 5 mg/L in 203 patients who had undergone a curative resection of NSCLC. Tomita et al. [12] found in 301 resectable NSCLC patients that combined use of CRP and neutrophil-to-lymphocyte index could discriminate the groups with different 5-year survival rates (74.18% in case of both values low vs. 20% in case of both values high). Alifano et al. [13] found preoperative CRP exceeding 20 mg/L to be a significant prognostic indicator in 300 stage I or II NSCLC patients treated with surgery.
Searching for a possible reason for the prognostic significance of CRP in NSCLC, we found in the present study a significant dependence between serum CRP and the pathological size of the tumour. Lee et al. [14] found a correlation between CRP and pathological tumour diameter, as well as between CRP and the signs of lymphovascular invasion, in 102 patients who underwent pulmonary resection. Alifano et al. found in lung cancer patients a correlation between serum CRP and the presence of chronic bronchitis, hypoalbuminaemia, pathologic stage of the disease and peritumoural vascular emboli. The other prognostic indicator found by our group was preoperative serum Cyfra 21-1 exceeding 2 ng/mL. Median survival in the groups with Cyfra 21-1 < 2 ng/mL and > 2 ng/mL were 79 (95%CI 14.85-88.2) months and 29 (95%CI 5.7-87.6) months, respectively (p < 0.026). Univariate analysis revealed that the risk of death in the patients with serum Cyfra 21-1 > 2 ng/ /mL was twice as high as for those with Cyfra 21-1 ≤ 2 ng/mL.
The prognostic value of Cyfra 21-1 was investigated by many authors, and most of them confirmed the negative prognostic significance of abnormal Cyfra 21-1 value [15] [16] [17] [18] [19] [20] (Table 5 ). In the reports concerning early-stage NSCLC treated with surgical resection, Cyfra 21-1 cut-offs used for assessment of prognosis were usually 2-2.8 ng/mL [18, 19] , and so were comparable to our cut off value of 2 ng/mL. The prognostic cut off value of Cyfra 21-1 in unresectable NSCLC was found to be much higher (4-18 ng/mL) [21, 22] . Cyfra 21-1 was previously described as a marker of squamous cell lung cancer (SCC) [23] . Subsequently, an elevated level of the marker was also found in serum of patients with adenocarcinoma and small cell lung cancer [22] . Similarly, in the present study we did not demonstrate significant differences between adenocarcinoma and SCC with respect to Cyfra 21-1 serum levels.
An interesting study concerning the origin of Cyfra 21-1 in serum was presented Kosacka et al. [24] , who compared tumour cytokeratin 19 immunostaining with Cyfra 21-1 value in serum in each of the studied patients. The authors found that the lower the Cyfra 21-1 in tumour tissue, the higher it was in serum. This finding confirms early observations that Cyfra 21-1 is released into circulation from necrotic tumour cells. Hanada et al. [25] found that the combination of weak cytokeratin 19 tumour expression and high serum Cyfra 21-1 levels was a predictor of poorer prognosis in 107 SCC patients.
These data may indicate that Cyfra 21-1 serum level reflects mainly the degree of tumour necrosis. Nevertheless, we could not demonstrate a correlation between serum Cyfra 21-1 and the percentage of tumour necrotic cells in the presented group of patients.
In the present study, we did not find the prognostic significance of preoperative serum CEA. One of the reasons was that elevated CEA was found also in the patients with early-stage tumours (mainly of adenocarcinoma histology), who survived five years from surgical resection without a relapse. The other reason for the lack of prognostic significance of CEA in our study was probably the small number of patients enrolled.
Most published data indicate the prognostic significance of CEA (Table 6 ) [26] [27] [28] [29] [30] [31] [32] [33] , but the majority of reports concern groups of patients with adenocarcinoma [28, 32] or with substantial adenocarcinoma predominance [18, 29, 31] . The authors of recently published articles have found that increased CEA concentration is a significant predictor of pN2 disease [1] , tumour diameter and visceral pleural invasion [34] , as well as recurrence after surgery [35] . Tomita et al. [36] described the combination of high CEA and SUV max > 6.6 on PET-CT scan as a prognostic variable.
www.pneumonologia.viamedica.pl On the other hand, Takahashi et al. [37] , who examined CEA in 649 surgically treated patients, found that 7 out of 28 patients with serum CEA > 30 ng/mL were long-term survivors (> 4 years). This is similar to our observation that 6/11 patients with CEA > 5 ng/mL survived 5 years or longer.
Important new data concerning the relation between high CEA serum concentration and the presence of EGFR mutation in adenocarcinoma were published in 2007 by Shoji et al. [38] and were recently confirmed by Zhang et al. [39] .
Summary
In the present study, concerning surgically treated NSCLC patients with clinical stage I and II of the disease, a preoperative CRP value exceeding 10 mg/L and Cyfra 21-1 higher than 2 ng/mL were the only negative prognostic indicators. Patho-www.pneumonologia.viamedica.pl logical tumour size and p-stage of disease were significant postoperative prognostic indicators.
